Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Published byArleen Matthews Modified over 6 years ago

Similar presentations

Presentation on theme: "Presented By Marco Colleoni at 2017 ASCO Annual Meeting"— Presentation transcript:

1 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
SOLE (Study of Letrozole Extension)<br /><br />A phase 3 randomized clinical trial of <br />continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer Presented By Marco Colleoni at 2017 ASCO Annual Meeting

2 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
S LE Presented By Marco Colleoni at 2017 ASCO Annual Meeting

3 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Slide 3 Presented By Marco Colleoni at 2017 ASCO Annual Meeting

4 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Extended Adjuvant Endocrine Therapy <br />for HR+ Early Breast Cancer Presented By Marco Colleoni at 2017 ASCO Annual Meeting

5 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Alternating “on-off” Letrozole Treatment as a Therapeutic Option to Prolong Sensitivity to Endocrine Treatment Presented By Marco Colleoni at 2017 ASCO Annual Meeting

6 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Effect of intermittent letrozole treatment in <br />MCF-7Ca xenografts Presented By Marco Colleoni at 2017 ASCO Annual Meeting

7 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Questions in Extended Adjuvant Endocrine Therapy <br />in HR+ Early Breast Cancer Presented By Marco Colleoni at 2017 ASCO Annual Meeting

8 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
SOLE: Study of Letrozole Extension<br />After 4 to 6 years of Prior Adjuvant Endocrine Therapy<br />Postmenopausal, HR-positive, Node-positive Presented By Marco Colleoni at 2017 ASCO Annual Meeting

9 SOLE Quality of Life Substudy
Presented By Marco Colleoni at 2017 ASCO Annual Meeting

10 Eligibility and Procedures
Presented By Marco Colleoni at 2017 ASCO Annual Meeting

11 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Endpoints Presented By Marco Colleoni at 2017 ASCO Annual Meeting

12 Statistical Considerations
Presented By Marco Colleoni at 2017 ASCO Annual Meeting

13 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Characteristics Presented By Marco Colleoni at 2017 ASCO Annual Meeting

14 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Results Presented By Marco Colleoni at 2017 ASCO Annual Meeting

15 Primary Endpoint: Disease-Free Survival
Presented By Marco Colleoni at 2017 ASCO Annual Meeting

16 Sites of First DFS Event
Presented By Marco Colleoni at 2017 ASCO Annual Meeting

17 Breast Cancer-Free Interval
Presented By Marco Colleoni at 2017 ASCO Annual Meeting

18 Distant Recurrence-Free Interval
Presented By Marco Colleoni at 2017 ASCO Annual Meeting

19 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Overall Survival Presented By Marco Colleoni at 2017 ASCO Annual Meeting

20 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Treatment Presented By Marco Colleoni at 2017 ASCO Annual Meeting

21 Selected Adverse Events: Worst Grade
Presented By Marco Colleoni at 2017 ASCO Annual Meeting

22 Quality of Life:<br />Change from Baseline to 12 and 24 Months
Presented By Marco Colleoni at 2017 ASCO Annual Meeting

23 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
SOLE: Conclusions Presented By Marco Colleoni at 2017 ASCO Annual Meeting

24 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
SOLE: Conclusions Presented By Marco Colleoni at 2017 ASCO Annual Meeting

25 Presented By Marco Colleoni at 2017 ASCO Annual Meeting
IBCSG Thanks Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Download ppt "Presented By Marco Colleoni at 2017 ASCO Annual Meeting"

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
ASCO G.U. 2014 Lawrence H. Einhorn.

ASCO G.U Lawrence H. Einhorn.
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.
Robertson JFR et al. J Clin Oncol 2009;27(27):

Robertson JFR et al. J Clin Oncol 2009;27(27):
Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
Study Of Letrozole Extension

Study Of Letrozole Extension
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,

HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.

Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.

The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
These slides were released by the speaker for internal use by Novartis

These slides were released by the speaker for internal use by Novartis
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Start or Switch?: Latest data from ABCSG/ARNO

Start or Switch?: Latest data from ABCSG/ARNO

Similar presentations

Ads by Google